Page O O O O
1 O O O O
of O O O O
5 O O O O
FREQUENTLY O O O O
ASKED O O O O
QUESTIONS O O O O
(FAQ) O O O O
ABOUT O O O O
VAXZEVRIA O O O O
VACCINE O O O O
Q1: O O O O
What Reason 5 O O
vaccine Reason 5 O O
is Reason 5 O O
being Reason 5 O O
registered? Reason 5 O O
A1: Reason 5 O O
The Reason 5 O O
Drug Reason 5 O O
Control Reason 5 O O
Authority Reason 5 O O
(DCA) Reason 5 O O
in Reason 5 O O
its Reason 5 O O
35 Reason 5 O O
4th Reason 5 O O
meeting Reason 5 O O
has Reason 5 O O
granted Reason 5 O O
Vaxzevria Reason 5 O O
Solution Reason 5 O O
for Reason 5 O O
Injection Reason 5 O O
(Product Reason 5 O O
Registration Reason 5 O O
REGISTRATION Reason 5 O O
on Reason 5 O O
2nd Reason 5 O O
March Reason 5 O O
2021. Reason 5 O O
Each Reason 5 O O
vial Reason 5 O O
of Reason 5 O O
Vaxzevria Reason 5 O O
contains Reason 5 O O
4ml Reason 5 O O
(8 Reason 5 O O
doses) Reason 5 O O
or Reason 5 O O
5ml Reason 5 O O
(10 Reason 5 O O
doses). Reason 5 O O
Subsequently, O O O O
a O O O O
second O O O O
source O O O O
of O O O O
the O O O O
same O O O O
vaccine O O O O
( O O O O
from O O O O
Thailand O O O O
and O O O O
South O O O O
Korea O O O O
) O O O O
was O O O O
also O O O O
granted O O O O
conditional O O O O
registration O O O O
in O O O O
the O O O O
35 O O O O
8th O O O O
& O O O O
366th O O O O
DCA O O O O
meeting O O O O
on O O O O
4th O O O O
June O O O O
2021 O O O O
& O O O O
17th O O O O
November O O O O
2021 O O O O
, O O O O
respectively. O O O O
Each O O O O
dose O O O O
(0.5ml) O O O O
of O O O O
Vaxzevria O O O O
contains O O O O
not O O O O
less O O O O
than O O O O
5 O O O O
x O O O O
1010 O O O O
viral O O O O
particles O O O O
of O O O O
recombinant, O O O O
replicant O O O O
-deficient O O O O
c O O O O
2021, O O O O
the O O O O
DCA O O O O
in O O O O
its O O O O
36 O O O O
6th O O O O
meeting O O O O
concluded O O O O
that O O O O
a O O O O
booster O O O O
dose O O O O
of O O O O
Vaxzevria O O O O
may O O O O
be O O O O
administered O O O O
at O O O O
least O O O O
6 O O O O
months O O O O
after O O O O
the O O O O
second O O O O
dose O O O O
in O O O O
individuals O O O O
aged O O O O
18 O O O O
ye O O O O
ars O O O O
and O O O O
above. O O O O
Q2: O O O O
What Reason 2 O O
are Reason 2 O O
the Reason 2 O O
conditions Reason 2 O O
of Reason 2 O O
the Reason 2 O O
registration? Reason 2 O O
A2: Reason 2 O O
Since Reason 2 O O
the Reason 2 O O
registration Reason 2 O O
application Reason 2 O O
is Reason 2 O O
via Reason 2 O O
"Conditional Reason 2 O O
Registration Reason 2 O O
of Reason 2 O O
Pharmaceutical Reason 2 O O
Products Reason 2 O O
durin Reason 2 O O
g Reason 2 O O
Disaster", Reason 2 O O
the Reason 2 O O
approval Reason 2 O O
is Reason 2 O O
based Reason 2 O O
on Reason 2 O O
rolling Reason 2 O O
submission Reason 2 O O
of Reason 2 O O
the Reason 2 O O
latest Reason 2 O O
data, Reason 2 O O
the Reason 2 O O
Product Reason 2 O O
Registration Reason 2 O O
Holder Reason 2 O O
(PRH) Reason 2 O O
will Reason 2 O O
need Reason 2 O O
to Reason 2 O O
ensure Reason 2 O O
all Reason 2 O O
outstanding Reason 2 O O
documents Reason 2 O O
are Reason 2 O O
to Reason 2 O O
be Reason 2 O O
submitted Reason 2 O O
and Reason 2 O O
deemed Reason 2 O O
satisfactory Reason 2 O O
by Reason 2 O O
NPRA Reason 2 O O
according Reason 2 O O
to Reason 2 O O
the Reason 2 O O
timeline Reason 2 O O
given. Reason 2 O O
Apart Reason 2 O O
from Reason 2 O O
that, Reason 2 O O
the Reason 2 O O
PRH Reason 2 O O
is Reason 2 O O
required Reason 2 O O
to Reason 2 O O
monitor Reason 2 O O
the Reason 2 O O
safety Reason 2 O O
profile Reason 2 O O
of Reason 2 O O
the Reason 2 O O
registered Reason 2 O O
vaccine Reason 2 O O
and Reason 2 O O
inform Reason 2 O O
NPRA Reason 2 O O
soonest Reason 2 O O
possible Reason 2 O O
of Reason 2 O O
any Reason 2 O O
untoward Reason 2 O O
events. Reason 2 O O
The O O O O
PRH O O O O
is O O O O
also O O O O
required O O O O
to O O O O
conduct O O O O
all O O O O
activities O O O O
planned O O O O
under O O O O
the O O O O
Risk O O O O
Management O O O O
Plan O O O O
(RMP) O O O O
as O O O O
well O O O O
as O O O O
submit O O O O
a O O O O
Monthly O O O O
Safety O O O O
Summary O O O O
Report O O O O
to O O O O
NPRA. O O O O
The O O O O
validity O O O O
of O O O O
this O O O O
conditional O O O O
ap O O O O
proval O O O O
is O O O O
one O O O O
( O O O O
1) O O O O
year. O O O O
During O O O O
this O O O O
period, O O O O
the O O O O
DCA O O O O
will O O O O
periodically O O O O
be O O O O
updated O O O O
with O O O O
all O O O O
necessary O O O O
information O O O O
related O O O O
to O O O O
the O O O O
quality, O O O O
safety O O O O
and O O O O
efficacy O O O O
of O O O O
this O O O O
vaccine. O O O O
The O O O O
conditional O O O O
registration O O O O
can O O O O
be O O O O
revoked O O O O
if O O O O
the O O O O
conditions O O O O
are O O O O
not O O O O
fulfilled O O O O
by O O O O
the O O O O
PRH O O O O
or O O O O
if O O O O
the O O O O
benefit O O O O
over O O O O
risk O O O O
of O O O O
the O O O O
vaccine O O O O
is O O O O
no O O O O
longer O O O O
deemed O O O O
beneficial. O O O O
Q3: O O O O
Why O O O O
is O O O O
Vaxzevria O O O O
granted O O O O
a O O O O
conditional O O O O
registration? O O O O
A3: O O O O
Clinical Reason 3 O O
studies Reason 3 O O
for Reason 3 O O
Vaxzevria Reason 3 O O
are Reason 3 O O
currently Reason 3 O O
still Reason 3 O O
on Reason 3 O O
-going. Reason 3 O O
The Reason 3 O O
current Reason 3 O O
interim Reason 3 O O
analysis Reason 3 O O
provided Reason 3 O O
show Reason 3 O O
a Reason 3 O O
positive Reason 3 O O
benefit Reason 3 O O
over Reason 3 O O
risk Reason 3 O O
and Reason 3 O O
hence Reason 3 O O
making Reason 3 O O
this Reason 3 O O
available Reason 3 O O
to Reason 3 O O
the Reason 3 O O
nation. Reason 3 O O
However, Reason 3 O O
further Reason 3 O O
monitoring Reason 3 O O
of Reason 3 O O
the Reason 3 O O
efficacy Reason 3 O O
and Reason 3 O O
safety Reason 3 O O
will Reason 3 O O
be Reason 3 O O
needed Reason 3 O O
in Reason 3 O O
order Reason 3 O O
to Reason 3 O O
ensure Reason 3 O O
that Reason 3 O O
the Reason 3 O O
benefit Reason 3 O O
-risk Reason 3 O O
balance Reason 3 O O
of Reason 3 O O
this Reason 3 O O
vaccine Reason 3 O O
remains Reason 3 O O
positive. Reason 3 O O
Page O O O O
2 O O O O
of O O O O
5 O O O O
Q4: O O O O
Who O O O O
can O O O O
be O O O O
given O O O O
Vaxzevria O O O O
? O O O O
A4: O O O O
Vaxzevria Reason 5 O O
is Reason 5 O O
indicated Reason 5 O O
for Reason 5 O O
the Reason 5 O O
active Reason 5 O O
immunization Reason 5 O O
to Reason 5 O O
prevent Reason 5 O O
COVID Reason 5 O O
-19 Reason 5 O O
caused Reason 5 O O
by Reason 5 O O
SARS Reason 5 O O
-CoV-2 Reason 5 O O
virus, Reason 5 O O
in Reason 5 O O
individuals Reason 5 O O
18 Reason 5 O O
years Reason 5 O O
of Reason 5 O O
age Reason 5 O O
and Reason 5 O O
older Reason 5 O O
. Reason 5 O O
The Reason 5 O O
use Reason 5 O O
of Reason 5 O O
this Reason 5 O O
vaccine Reason 5 O O
should Reason 5 O O
be Reason 5 O O
in Reason 5 O O
accordance Reason 5 O O
with Reason 5 O O
the Reason 5 O O
recommendations Reason 5 O O
by Reason 5 O O
the Reason 5 O O
Ministry Reason 5 O O
of Reason 5 O O
Health Reason 5 O O
Malaysia. Reason 5 O O
Q5: O O O O
Who O O O O
can't O O O O
be O O O O
given O O O O
Vaxzevria O O O O
? O O O O
A5: O O O O
Vaxzevria Reason 1 O O
should Reason 1 O O
not Reason 1 O O
be Reason 1 O O
given Reason 1 O O
to Reason 1 O O
individuals Reason 1 O O
who Reason 1 O O
are Reason 1 O O
known Reason 1 O O
to Reason 1 O O
have Reason 1 O O
allergic Reason 1 O O
reactions Reason 1 O O
to Reason 1 O O
any Reason 1 O O
of Reason 1 O O
the Reason 1 O O
ingredients Reason 1 O O
in Reason 1 O O
the Reason 1 O O
vaccine Reason 1 O O
[ Reason 1 O O
L-Histidine, Reason 1 O O
L Reason 1 O O
-Histidine Reason 1 O O
hydrochloride Reason 1 O O
monohydrate, Reason 1 O O
Magnesium Reason 1 O O
and Reason 1 O O
Disodium Reason 1 O O
edetate Reason 1 O O
(dihydrate) Reason 1 O O
]. Reason 1 O O
The Reason 1 O O
second Reason 1 O O
dose Reason 1 O O
of Reason 1 O O
the Reason 1 O O
vaccine Reason 1 O O
should Reason 1 O O
not Reason 1 O O
be Reason 1 O O
given Reason 1 O O
to Reason 1 O O
individuals Reason 1 O O
who Reason 1 O O
had Reason 1 O O
a Reason 1 O O
severe Reason 1 O O
allergic Reason 1 O O
reaction Reason 1 O O
after Reason 1 O O
the Reason 1 O O
first Reason 1 O O
dose Reason 1 O O
of Reason 1 O O
this Reason 1 O O
vaccine. Reason 1 O O
Q6: O O O O
Can O O O O
immunocompromised O O O O
individuals O O O O
receive O O O O
Vaxzevria O O O O
? O O O O
A6: O O O O
At Reason 3 O O
the Reason 3 O O
moment, Reason 3 O O
there Reason 3 O O
is Reason 3 O O
insufficient Reason 3 O O
clinical Reason 3 O O
evidence Reason 3 O O
to Reason 3 O O
support Reason 3 O O
vaccination Reason 3 O O
in Reason 3 O O
immunocompromised Reason 3 O O
individuals, Reason 3 O O
including Reason 3 O O
those Reason 3 O O
receiving Reason 3 O O
immunosuppressant Reason 3 O O
therapy. Reason 3 O O
However, Reason 3 O O
these Reason 3 O O
recom Reason 3 O O
mendations Reason 3 O O
may Reason 3 O O
change Reason 3 O O
as Reason 3 O O
more Reason 3 O O
clinical Reason 3 O O
data Reason 3 O O
is Reason 3 O O
obtained. Reason 3 O O
Please Reason 3 O O
speak Reason 3 O O
to Reason 3 O O
your Reason 3 O O
doctor Reason 3 O O
to Reason 3 O O
identify Reason 3 O O
if Reason 3 O O
you Reason 3 O O
may Reason 3 O O
be Reason 3 O O
a Reason 3 O O
suitable Reason 3 O O
candidate Reason 3 O O
to Reason 3 O O
receive Reason 3 O O
the Reason 3 O O
vaccine. Reason 3 O O
Q7: O O O O
If O O O O
I O O O O
have O O O O
the O O O O
following O O O O
conditions, O O O O
or O O O O
receiving O O O O
or O O O O
have O O O O
received O O O O
these O O O O
treatments, O O O O
can O O O O
I O O O O
receive O O O O
the O O O O
vaccine? O O O O
A7: O O O O
Please O O O O
consult O O O O
your O O O O
doctor O O O O
if O O O O
you: O O O O
have O O O O
any O O O O
form O O O O
of O O O O
allergies, O O O O
bleeding O O O O
disorder, O O O O
or O O O O
taking O O O O
any O O O O
blood O O O O
thinning O O O O
medications O O O O
recently O O O O
or O O O O
currently O O O O
receiving O O O O
treatment O O O O
for O O O O
cancer, O O O O
organ O O O O
or O O O O
stem O O O O
cell O O O O
transplantation O O O O
had O O O O
a O O O O
previous O O O O
hist O O O O
ory O O O O
of O O O O
COVID O O O O
-19 O O O O
infection, O O O O
had O O O O
previously O O O O
received O O O O
another O O O O
COVID O O O O
-19 O O O O
vaccine O O O O
(whether O O O O
during O O O O
an O O O O
immunisation O O O O
program O O O O
or O O O O
was O O O O
involved O O O O
as O O O O
a O O O O
subject O O O O
in O O O O
a O O O O
COVID O O O O
-19 O O O O
clinical O O O O
study) O O O O
, O O O O
or O O O O
previously O O O O
received O O O O
passive O O O O
antibodies O O O O
therapy O O O O
for O O O O
COVID O O O O
-19. O O O O
You O O O O
may O O O O
receive O O O O
the O O O O
vaccine O O O O
even O O O O
if O O O O
you O O O O
have O O O O
the O O O O
above O O O O
conditions. O O O O
However, O O O O
please O O O O
speak O O O O
with O O O O
your O O O O
doctor O O O O
before O O O O
deciding O O O O
if O O O O
you O O O O
are O O O O
a O O O O
suitable O O O O
candidate. O O O O
Q8: O O O O
How O O O O
is O O O O
Vaxzevria O O O O
given? O O O O
A8: O O O O
As O O O O
a O O O O
primary O O O O
course, O O O O
Vaxzevria O O O O
should O O O O
be O O O O
injected O O O O
into O O O O
the O O O O
deltoid O O O O
muscle O O O O
of O O O O
the O O O O
upper O O O O
arm O O O O
in O O O O
a O O O O
course O O O O
of O O O O
2 O O O O
doses O O O O
(0.5mL O O O O
each). O O O O
The O O O O
second O O O O
dose O O O O
is O O O O
to O O O O
be O O O O
taken O O O O
between O O O O
4 O O O O
and O O O O
12 O O O O
weeks O O O O
(28 O O O O
to O O O O
84 O O O O
days O O O O
) O O O O
after O O O O
the O O O O
first O O O O
dose. O O O O
A O O O O
booster O O O O
dose O O O O
of O O O O
Vaxzevria O O O O
may O O O O
be O O O O
given O O O O
approximately O O O O
6 O O O O
months O O O O
aft O O O O
er O O O O
the O O O O
second O O O O
dose O O O O
in O O O O
individuals O O O O
aged O O O O
18 O O O O
years O O O O
and O O O O
above. O O O O
The O O O O
need O O O O
for O O O O
when O O O O
and O O O O
whom O O O O
to O O O O
be O O O O
given O O O O
the O O O O
booster O O O O
dose O O O O
will O O O O
be O O O O
determined O O O O
by O O O O
local O O O O
recommendations O O O O
. O O O O
Page O O O O
3 O O O O
of O O O O
5 O O O O
Q9: O O O O
How O O O O
well O O O O
does O O O O
Vaxzevria O O O O
prevent O O O O
COVID O O O O
-19? O O O O
A9: O O O O
In Reason 5 O O
the Reason 5 O O
pooled Reason 5 O O
analysis Reason 5 O O
of Reason 5 O O
the Reason 5 O O
two Reason 5 O O
ongoing Reason 5 O O
Phase Reason 5 O O
III Reason 5 O O
clinical Reason 5 O O
trial Reason 5 O O
s, Reason 5 O O
the Reason 5 O O
vaccine Reason 5 O O
was Reason 5 O O
59.5% Reason 5 O O
(95%CI Reason 5 O O
45.8-69.7) Reason 5 O O
effective Reason 5 O O
in Reason 5 O O
preventing Reason 5 O O
symptomatic Reason 5 O O
COVID Reason 5 O O
-19 Reason 5 O O
disease Reason 5 O O
following Reason 5 O O
completion Reason 5 O O
of Reason 5 O O
2 Reason 5 O O
doses Reason 5 O O
of Reason 5 O O
the Reason 5 O O
vaccine Reason 5 O O
regime. Reason 5 O O
This Reason 5 O O
fulfilled Reason 5 O O
the Reason 5 O O
efficacy Reason 5 O O
standard Reason 5 O O
as Reason 5 O O
recommended Reason 5 O O
by Reason 5 O O
WHO, Reason 5 O O
where Reason 5 O O
the Reason 5 O O
primary Reason 5 O O
efficacy Reason 5 O O
endpoint Reason 5 O O
point Reason 5 O O
estimate Reason 5 O O
for Reason 5 O O
a Reason 5 O O
placebo Reason 5 O O
-controlled Reason 5 O O
efficacy Reason 5 O O
trial Reason 5 O O
should Reason 5 O O
be Reason 5 O O
at Reason 5 O O
least Reason 5 O O
50%, Reason 5 O O
and Reason 5 O O
the Reason 5 O O
lower Reason 5 O O
bound Reason 5 O O
of Reason 5 O O
confidence Reason 5 O O
interval Reason 5 O O
(CI) Reason 5 O O
should Reason 5 O O
be Reason 5 O O
>30%. Reason 5 O O
More Reason 5 O O
data Reason 5 O O
is Reason 5 O O
expected Reason 5 O O
from Reason 5 O O
ongoing Reason 5 O O
Phase Reason 5 O O
III Reason 5 O O
trials Reason 5 O O
on Reason 5 O O
a Reason 5 O O
rolling Reason 5 O O
review Reason 5 O O
basis. Reason 5 O O
Q10: O O O O
How O O O O
long O O O O
will O O O O
Vaxzevria O O O O
provide O O O O
protection? O O O O
A10: O O O O
As Reason 3 O O
the Reason 3 O O
clinical Reason 3 O O
trial Reason 3 O O
is Reason 3 O O
still Reason 3 O O
currently Reason 3 O O
ongoing, Reason 3 O O
no Reason 3 O O
data Reason 3 O O
is Reason 3 O O
available Reason 3 O O
to Reason 3 O O
inform Reason 3 O O
about Reason 3 O O
the Reason 3 O O
duration Reason 3 O O
of Reason 3 O O
protection Reason 3 O O
that Reason 3 O O
the Reason 3 O O
vaccine Reason 3 O O
will Reason 3 O O
provide. Reason 3 O O
This Reason 3 O O
however Reason 3 O O
will Reason 3 O O
be Reason 3 O O
made Reason 3 O O
known Reason 3 O O
once Reason 3 O O
updated Reason 3 O O
data Reason 3 O O
is Reason 3 O O
availab Reason 3 O O
le. Reason 3 O O
Q11: O O O O
Can O O O O
people O O O O
who O O O O
have O O O O
already O O O O
had O O O O
COVID O O O O
-19 O O O O
get O O O O
Vaxzevria O O O O
? O O O O
A11: O O O O
Available Reason 5 O O
data Reason 5 O O
indicate Reason 5 O O
that Reason 5 O O
Vaxzevria Reason 5 O O
is Reason 5 O O
safe Reason 5 O O
when Reason 5 O O
given Reason 5 O O
in Reason 5 O O
people Reason 5 O O
with Reason 5 O O
evidence Reason 5 O O
of Reason 5 O O
prior Reason 5 O O
COVID Reason 5 O O
-19 Reason 5 O O
disease. Reason 5 O O
Since Reason 5 O O
previously Reason 5 O O
infected Reason 5 O O
individuals Reason 5 O O
c Reason 5 O O
an Reason 5 O O
be Reason 5 O O
at Reason 5 O O
risk Reason 5 O O
of Reason 5 O O
COVID Reason 5 O O
-19 Reason 5 O O
(i.e. Reason 5 O O
reinfection), Reason 5 O O
vaccination Reason 5 O O
may Reason 5 O O
be Reason 5 O O
offered Reason 5 O O
to Reason 5 O O
them. Reason 5 O O
However, Reason 5 O O
please Reason 5 O O
speak Reason 5 O O
with Reason 5 O O
your Reason 5 O O
doctor Reason 5 O O
before Reason 5 O O
deciding Reason 5 O O
if Reason 5 O O
you Reason 5 O O
are Reason 5 O O
a Reason 5 O O
suitable Reason 5 O O
candidate. Reason 5 O O
Q12: O O O O
Can O O O O
pregnant O O O O
or O O O O
breastfeeding O O O O
women O O O O
receive O O O O
Vaxzevria O O O O
? O O O O
A12: O O O O
Pregnant Reason 3 O O
or Reason 3 O O
breastfeeding Reason 3 O O
women Reason 3 O O
were Reason 3 O O
excluded Reason 3 O O
from Reason 3 O O
the Reason 3 O O
clinical Reason 3 O O
trials. Reason 3 O O
Since Reason 3 O O
no Reason 3 O O
data Reason 3 O O
on Reason 3 O O
the Reason 3 O O
safety Reason 3 O O
and Reason 3 O O
efficacy Reason 3 O O
of Reason 3 O O
this Reason 3 O O
vaccine Reason 3 O O
is Reason 3 O O
available Reason 3 O O
in Reason 3 O O
these Reason 3 O O
populations Reason 3 O O
, Reason 3 O O
current Reason 3 O O
evidence Reason 3 O O
is Reason 3 O O
unable Reason 3 O O
to Reason 3 O O
make Reason 3 O O
recommendations Reason 3 O O
for Reason 3 O O
these Reason 3 O O
groups Reason 3 O O
until Reason 3 O O
further Reason 3 O O
available Reason 3 O O
data Reason 3 O O
is Reason 3 O O
obtained. Reason 3 O O
However, Reason 3 O O
please Reason 3 O O
speak Reason 3 O O
to Reason 3 O O
your Reason 3 O O
do Reason 3 O O
ctor Reason 3 O O
to Reason 3 O O
identify Reason 3 O O
if Reason 3 O O
you Reason 3 O O
may Reason 3 O O
be Reason 3 O O
a Reason 3 O O
suitable Reason 3 O O
candidate Reason 3 O O
to Reason 3 O O
receive Reason 3 O O
the Reason 3 O O
vaccine. Reason 3 O O
Q13: O O O O
Can O O O O
the O O O O
elderly O O O O
receive O O O O
Vaxzevria O O O O
? O O O O
A13: O O O O
The Reason 3 O O
vaccine Reason 3 O O
is Reason 3 O O
indicated Reason 3 O O
for Reason 3 O O
people Reason 3 O O
aged Reason 3 O O
18 Reason 3 O O
years Reason 3 O O
and Reason 3 O O
above. Reason 3 O O
However, Reason 3 O O
based Reason 3 O O
on Reason 3 O O
the Reason 3 O O
currently Reason 3 O O
available Reason 3 O O
clinical Reason 3 O O
data, Reason 3 O O
there Reason 3 O O
is Reason 3 O O
a Reason 3 O O
limited Reason 3 O O
number Reason 3 O O
of Reason 3 O O
subjects Reason 3 O O
aged Reason 3 O O
55 Reason 3 O O
years Reason 3 O O
and Reason 3 O O
above Reason 3 O O
recruited Reason 3 O O
and Reason 3 O O
analyzed Reason 3 O O
therefore Reason 3 O O
the Reason 3 O O
data Reason 3 O O
in Reason 3 O O
this Reason 3 O O
population Reason 3 O O
are Reason 3 O O
limited. Reason 3 O O
Based Reason 3 O O
on Reason 3 O O
early Reason 3 O O
phase Reason 3 O O
data, Reason 3 O O
administration Reason 3 O O
of Reason 3 O O
Vaxzevria Reason 3 O O
to Reason 3 O O
individuals Reason 3 O O
aged Reason 3 O O
55 Reason 3 O O
years Reason 3 O O
and Reason 3 O O
above Reason 3 O O
has Reason 3 O O
shown Reason 3 O O
adequate Reason 3 O O
and Reason 3 O O
similar Reason 3 O O
neutralizing Reason 3 O O
antibody Reason 3 O O
titres Reason 3 O O
as Reason 3 O O
in Reason 3 O O
younger Reason 3 O O
adults. Reason 3 O O
At Reason 3 O O
present, Reason 3 O O
it Reason 3 O O
is Reason 3 O O
recommended Reason 3 O O
that Reason 3 O O
vaccination Reason 3 O O
for Reason 3 O O
people Reason 3 O O
aged Reason 3 O O
55 Reason 3 O O
and Reason 3 O O
above Reason 3 O O
should Reason 3 O O
be Reason 3 O O
cautiously Reason 3 O O
considered, Reason 3 O O
its Reason 3 O O
necessity Reason 3 O O
should Reason 3 O O
be Reason 3 O O
evaluated Reason 3 O O
based Reason 3 O O
on Reason 3 O O
their Reason 3 O O
health Reason 3 O O
condition Reason 3 O O
and Reason 3 O O
exposure Reason 3 O O
risk. Reason 3 O O
Q14: O O O O
Can O O O O
children O O O O
receive O O O O
Vaxzevria O O O O
? O O O O
A14: O O O O
Currently O O O O
in O O O O
Malaysia, O O O O
the O O O O
vaccine O O O O
is O O O O
indicated O O O O
for O O O O
individuals O O O O
18 O O O O
years O O O O
of O O O O
age O O O O
and O O O O
older. O O O O
This Reason 1 O O
is Reason 1 O O
because Reason 1 O O
there Reason 1 O O
is Reason 1 O O
not Reason 1 O O
enough Reason 1 O O
data Reason 1 O O
yet Reason 1 O O
to Reason 1 O O
determine Reason 1 O O
the Reason 1 O O
effectiveness Reason 1 O O
and Reason 1 O O
safet Reason 1 O O
y Reason 1 O O
of Reason 1 O O
this Reason 1 O O
vaccine Reason 1 O O
in Reason 1 O O
those Reason 1 O O
under Reason 1 O O
18 Reason 1 O O
years Reason 1 O O
old. Reason 1 O O
Hence Reason 1 O O
children Reason 1 O O
below Reason 1 O O
the Reason 1 O O
age Reason 1 O O
of Reason 1 O O
18 Reason 1 O O
should Reason 1 O O
not Reason 1 O O
take Reason 1 O O
the Reason 1 O O
vaccine Reason 1 O O
until Reason 1 O O
further Reason 1 O O
data Reason 1 O O
is Reason 1 O O
made Reason 1 O O
available. Reason 1 O O
Page O O O O
4 O O O O
of O O O O
5 O O O O
Q15: O O O O
What O O O O
are O O O O
the O O O O
side O O O O
effects O O O O
of O O O O
Vaxzevria O O O O
? O O O O
A15: O O O O
Vaxzevria Reason 2 O O
can Reason 2 O O
cause Reason 2 O O
the Reason 2 O O
following Reason 2 O O
side Reason 2 O O
effects: Reason 2 O O
Very Reason 2 O O
common Reason 2 O O
side Reason 2 O O
effects Reason 2 O O
(may Reason 2 O O
affect Reason 2 O O
more Reason 2 O O
than Reason 2 O O
1 Reason 2 O O
in Reason 2 O O
10 Reason 2 O O
people): Reason 2 O O
headache, Reason 2 O O
nausea, Reason 2 O O
injection Reason 2 O O
site Reason 2 O O
tenderness Reason 2 O O
, Reason 2 O O
pain, Reason 2 O O
warmth, Reason 2 O O
itching Reason 2 O O
or Reason 2 O O
bruising, Reason 2 O O
fatigue, Reason 2 O O
malaise, Reason 2 O O
feverishness Reason 2 O O
, Reason 2 O O
chills Reason 2 O O
, Reason 2 O O
muscle Reason 2 O O
ache Reason 2 O O
, Reason 2 O O
and Reason 2 O O
joint Reason 2 O O
pain. Reason 2 O O
Common Reason 2 O O
side Reason 2 O O
effects Reason 2 O O
(may Reason 2 O O
affect Reason 2 O O
up Reason 2 O O
to Reason 2 O O
1 Reason 2 O O
in Reason 2 O O
10 Reason 2 O O
people): Reason 2 O O
injection Reason 2 O O
site Reason 2 O O
swelling Reason 2 O O
or Reason 2 O O
redness Reason 2 O O
, Reason 2 O O
fever Reason 2 O O
(38Â°C) Reason 2 O O
, Reason 2 O O
vomiting Reason 2 O O
, Reason 2 O O
diarrhea Reason 2 O O
, Reason 2 O O
pain Reason 2 O O
in Reason 2 O O
the Reason 2 O O
extremities Reason 2 O O
(hand Reason 2 O O
and Reason 2 O O
foot), Reason 2 O O
flu-like Reason 2 O O
symptoms Reason 2 O O
(such Reason 2 O O
as Reason 2 O O
high Reason 2 O O
temperature, Reason 2 O O
sore Reason 2 O O
throat, Reason 2 O O
runny Reason 2 O O
nose, Reason 2 O O
cough Reason 2 O O
and Reason 2 O O
chills) Reason 2 O O
and Reason 2 O O
thrombocytopenia Reason 2 O O
( Reason 2 O O
low Reason 2 O O
levels Reason 2 O O
of Reason 2 O O
blood Reason 2 O O
platelets Reason 2 O O
). Reason 2 O O
Uncommon Reason 2 O O
side Reason 2 O O
effects Reason 2 O O
(may Reason 2 O O
affect Reason 2 O O
up Reason 2 O O
to Reason 2 O O
1 Reason 2 O O
in Reason 2 O O
100 Reason 2 O O
people): Reason 2 O O
lymphadenopathy Reason 2 O O
(enlarged Reason 2 O O
lymph Reason 2 O O
nodes Reason 2 O O
), Reason 2 O O
decreased Reason 2 O O
appetite Reason 2 O O
, Reason 2 O O
somnolence Reason 2 O O
, Reason 2 O O
excessive Reason 2 O O
sweating, Reason 2 O O
itchy Reason 2 O O
skin Reason 2 O O
, Reason 2 O O
rash Reason 2 O O
and Reason 2 O O
abdominal Reason 2 O O
pain Reason 2 O O
. Reason 2 O O
Very Reason 2 O O
rare Reason 2 O O
(may Reason 2 O O
affect Reason 2 O O
up Reason 2 O O
to Reason 2 O O
1 Reason 2 O O
in Reason 2 O O
10,000 Reason 2 O O
people) Reason 2 O O
: Reason 2 O O
thrombosis Reason 2 O O
in Reason 2 O O
combination Reason 2 O O
with Reason 2 O O
thrombocytopenia Reason 2 O O
(major Reason 2 O O
blood Reason 2 O O
clots Reason 2 O O
in Reason 2 O O
combination Reason 2 O O
with Reason 2 O O
low Reason 2 O O
levels Reason 2 O O
of Reason 2 O O
blood Reason 2 O O
platelets Reason 2 O O
). Reason 2 O O
The O O O O
majority O O O O
of O O O O
adverse O O O O
reactions O O O O
were O O O O
mild O O O O
to O O O O
moderate O O O O
in O O O O
severity O O O O
and O O O O
usually O O O O
resolved O O O O
within O O O O
a O O O O
few O O O O
days O O O O
of O O O O
vaccination. O O O O
When O O O O
compared O O O O
with O O O O
the O O O O
first O O O O
dose, O O O O
adverse O O O O
reactions O O O O
reported O O O O
after O O O O
the O O O O
second O O O O
dose O O O O
were O O O O
milder O O O O
and O O O O
reported O O O O
less O O O O
frequently. O O O O
There O O O O
is O O O O
a O O O O
remote O O O O
chance O O O O
that O O O O
the O O O O
vaccine O O O O
could O O O O
cause O O O O
a O O O O
severe O O O O
allergic O O O O
reaction O O O O
even O O O O
though O O O O
th O O O O
e O O O O
causal O O O O
relationship O O O O
has O O O O
not O O O O
been O O O O
ascertained O O O O
yet O O O O
. O O O O
A O O O O
severe O O O O
allergic O O O O
reaction O O O O
would O O O O
usually O O O O
occur O O O O
within O O O O
a O O O O
few O O O O
minutes O O O O
to O O O O
one O O O O
hour O O O O
after O O O O
getting O O O O
a O O O O
dose O O O O
of O O O O
the O O O O
vaccine. O O O O
Signs O O O O
of O O O O
a O O O O
severe O O O O
allergic O O O O
reaction O O O O
can O O O O
include O O O O
difficulty O O O O
in O O O O
breathing, O O O O
swelling O O O O
of O O O O
yo O O O O
ur O O O O
face O O O O
and O O O O
throat, O O O O
a O O O O
fast O O O O
heartbeat, O O O O
a O O O O
bad O O O O
rash O O O O
all O O O O
over O O O O
your O O O O
body O O O O
or O O O O
dizziness O O O O
and O O O O
weakness. O O O O
Recipient O O O O
will O O O O
be O O O O
monitored O O O O
15 O O O O
minutes O O O O
after O O O O
the O O O O
administration O O O O
of O O O O
this O O O O
vaccine O O O O
at O O O O
the O O O O
vaccination O O O O
center O O O O
. O O O O
During O O O O
the O O O O
marketing O O O O
of O O O O
Vaxzevria O O O O
in O O O O
Malaysia, O O O O
NPRA O O O O
will O O O O
monitor O O O O
its O O O O
use O O O O
to O O O O
ensure O O O O
effectiveness O O O O
and O O O O
safety. O O O O
Please O O O O
inform O O O O
your O O O O
healthcare O O O O
providers O O O O
or O O O O
report O O O O
any O O O O
side O O O O
effects O O O O
to O O O O
the O O O O
National O O O O
Centre O O O O
for O O O O
Adverse O O O O
Drug O O O O
Reaction O O O O
Monitoring O O O O
by O O O O
visiting O O O O
the O O O O
website O O O O
npra.gov.my O O O O
[Consumers O O O O
> O O O O
Reporting O O O O
Side O O O O
Effects O O O O
to O O O O
Medicines O O O O
(ConSERF) O O O O
or O O O O
Vaccines O O O O
(AEFI)]. O O O O
Q16: O O O O
Can Reason 2 O O
Vaxzevria Reason 2 O O
cause Reason 2 O O
thromboembolic Reason 2 O O
events Reason 2 O O
(blood Reason 2 O O
clots Reason 2 O O
) Reason 2 O O
following Reason 2 O O
vaccination Reason 2 O O
? Reason 2 O O
A16: Reason 2 O O
Based Reason 2 O O
on Reason 2 O O
the Reason 2 O O
known Reason 2 O O
clinical Reason 2 O O
data, Reason 2 O O
thromboembolic Reason 2 O O
events Reason 2 O O
are Reason 2 O O
not Reason 2 O O
among Reason 2 O O
the Reason 2 O O
known Reason 2 O O
or Reason 2 O O
typical Reason 2 O O
side Reason 2 O O
effects Reason 2 O O
of Reason 2 O O
Vaxzevria Reason 2 O O
. Reason 2 O O
Following Reason 2 O O
vaccination Reason 2 O O
of Reason 2 O O
Vaxzevria Reason 2 O O
, Reason 2 O O
major Reason 2 O O
blood Reason 2 O O
clots Reason 2 O O
in Reason 2 O O
combination Reason 2 O O
with Reason 2 O O
low Reason 2 O O
levels Reason 2 O O
of Reason 2 O O
blood Reason 2 O O
platelets Reason 2 O O
have Reason 2 O O
been Reason 2 O O
observed Reason 2 O O
very Reason 2 O O
rarely Reason 2 O O
(with Reason 2 O O
a Reason 2 O O
frequency Reason 2 O O
less Reason 2 O O
than Reason 2 O O
1 Reason 2 O O
in Reason 2 O O
10,000 Reason 2 O O
vaccinated Reason 2 O O
individuals). Reason 2 O O
Blood Reason 2 O O
clots Reason 2 O O
can Reason 2 O O
occur Reason 2 O O
in Reason 2 O O
blood Reason 2 O O
vessels Reason 2 O O
of Reason 2 O O
the Reason 2 O O
heart, Reason 2 O O
brain Reason 2 O O
or Reason 2 O O
other Reason 2 O O
organs. Reason 2 O O
The O O O O
majority O O O O
of O O O O
the O O O O
events O O O O
Page O O O O
5 O O O O
of O O O O
5 O O O O
occurred O O O O
w O O O O
ithin O O O O
the O O O O
first O O O O
21 O O O O
days O O O O
following O O O O
vaccination O O O O
and O O O O
occurred O O O O
in O O O O
individuals O O O O
aged O O O O
18-59 O O O O
years O O O O
old. O O O O
It O O O O
is O O O O
important O O O O
to O O O O
seek O O O O
immediate O O O O
medical O O O O
attention O O O O
if O O O O
you O O O O
develop O O O O
symptoms O O O O
such O O O O
as O O O O
confusion, O O O O
seizures, O O O O
shortness O O O O
of O O O O
breath, O O O O
chest O O O O
pain, O O O O
leg O O O O
swelling, O O O O
leg O O O O
pain, O O O O
persistent O O O O
abdominal O O O O
pain O O O O
following O O O O
vaccination. O O O O
Also, O O O O
please O O O O
seek O O O O
immediate O O O O
medical O O O O
attention O O O O
if O O O O
you O O O O
experience O O O O
after O O O O
a O O O O
few O O O O
days O O O O
severe O O O O
or O O O O
persistent O O O O
headaches O O O O
or O O O O
blurred O O O O
vision O O O O
after O O O O
vaccination, O O O O
or O O O O
experience O O O O
skin O O O O
bruising O O O O
or O O O O
pinpoint O O O O
round O O O O
spots O O O O
beyond O O O O
the O O O O
site O O O O
of O O O O
vaccination O O O O
which O O O O
appears O O O O
after O O O O
a O O O O
few O O O O
days. O O O O
Q17: O O O O
What Reason 5 O O
should Reason 5 O O
I Reason 5 O O
do Reason 5 O O
after Reason 5 O O
I Reason 5 O O
am Reason 5 O O
vaccinated? Reason 5 O O
A17: Reason 5 O O
All Reason 5 O O
individuals Reason 5 O O
should Reason 5 O O
continue Reason 5 O O
to Reason 5 O O
follow Reason 5 O O
the Reason 5 O O
country's Reason 5 O O
SOP. Reason 5 O O
Practice Reason 5 O O
the Reason 5 O O
3Ws Reason 5 O O
(Wash Reason 5 O O
, Reason 5 O O
Wear Reason 5 O O
, Reason 5 O O
Warn Reason 5 O O
) Reason 5 O O
and Reason 5 O O
avoid Reason 5 O O
the Reason 5 O O
3Cs Reason 5 O O
( Reason 5 O O
Crowded Reason 5 O O
space, Reason 5 O O
Confined Reason 5 O O
space, Reason 5 O O
Close Reason 5 O O
conversation). Reason 5 O O
For O O O O
further O O O O
information O O O O
regarding O O O O
Vaxzevria O O O O
Solution O O O O
for O O O O
Injection O O O O
, O O O O
please O O O O
refer O O O O
to O O O O
the O O O O
Package O O O O
Insert O O O O
and O O O O
Patient O O O O
Information O O O O
Leaflet. O O O O
Vaxzevria O O O O
Solution O O O O
for O O O O
Injection O O O O
(Netherlands) O O O O
(MAL21036009ACZ) O O O O
Injection O O O O
(Thailand) O O O O
Injection O O O O
(South O O O O
